The efficacy and safety of Mirogabalin for chronic pain derived from neuropathic pain

The efficacy and safety of Mirogabalin for chronic pain derived from neuropathic pain - The efficacy and safety of Mirogabalin

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037216

Enrollment

100

Registered

2019-07-01

Start date

2019-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pain, Neuropathic pain

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chronic pain, Neuropathic pain

Exclusion criteria

Exclusion criteria: Patients who cannot answer questionnaires

Design outcomes

Primary

Measure	Time frame
NRS(Numerical rating scale) is assessed at, before perscription, in 2 weeks, and in 1/2/3/6 months.	—

Secondary

Measure	Time frame
Side effects and QOL scores are assessed, before perscription, in 2 weeks, and in 1/2/3/6 months.	—

Countries

Japan

Contacts

Public ContactChiharu Hayashi

NTT Medical Center Tokyo Pain clinic

thousand.sunny.e.b.d@gmail.com03-3448-6111

Outcome results